How many doses of Teclistamab are needed for one course of treatment?

Teritusumab (Teclistamab-cqyv) is an innovative bispecific antibody drug that achieves precise activation of the immune system by targetingB cell maturation antigen (BCMA) and T cell receptor CD3. It is used to treat patients with relapsed or refractory multiple myeloma (RRMM). Such patients usually continue to progress after multiple lines of treatment with proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies. Therefore, teritusumab has become an important breakthrough in treatment in recent years. According to the data, teritusumab is administered by subcutaneous injection, and its treatment schedule has a unique model of “increasing dose + maintenance treatment”.

The initial phase is a dose escalation period, usually divided into three injections: 0.06 mg/kg is injected on the first day as incremental dose 1, 0.3 mg/kg is injected as incremental dose 2 on the fourth day, and the official treatment dose is 1.5 mg/kg starting on the seventh day. After that, the maintenance period will be entered, with subcutaneous injections once a week, which is equivalent to injecting one drug every 7 days, until the disease progresses or the patient develops intolerable toxic reactions. If patients achieve and maintain complete remission (CR) or better treatment response after 6 months of treatment, they can switch to injections every two weeks to reduce the treatment burden. The total number of injections in each course of treatment varies depending on the patient's individual response, disease control, and the doctor's individual adjustments. Generally speaking, a standard course of treatment can include multiple consecutive administrations.

It is worth noting that teritusumab requires hospitalization for observation during the dose-increasing phase, and 48-hour monitoring is usually required after each dose-increasing dose to prevent immune-related reactions such as cytokine release syndrome (CRS). This incremental approach can effectively reduce the risk of initial immune activation and enhance safety.

Reference materials:https://www.tecvayli.com/